{"id":12404,"date":"2008-07-07T18:30:00","date_gmt":"2008-07-07T16:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/rassegna-stampa-farmaceutica-dal-4-al-7-luglio-di-aboutpharma\/"},"modified":"2008-07-07T18:30:00","modified_gmt":"2008-07-07T16:30:00","slug":"rassegna-stampa-farmaceutica-dal-4-al-7-luglio-di-aboutpharma","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/rassegna-stampa-farmaceutica-dal-4-al-7-luglio-di-aboutpharma\/","title":{"rendered":"PHARMACEUTICAL PRESS REVIEW from 4 to 7 July of AboutPharma"},"content":{"rendered":"<p class=\"MsoNormal\"><strong><strong><font face=\"Arial\" color=\"#ff0000\" size=\"4\"><span style=\"font-size: 14pt; color: red; font-family: Arial\">Press Review from<\/span><\/font><\/strong><\/strong><font face=\"Arial\" color=\"#ff0000\" size=\"4\"><span style=\"font-size: 14pt; color: red; font-family: Arial\"> <strong><span style=\"font-weight: bold\">04<strong><strong><font face=\"Arial\"><span style=\"font-family: Arial\">\/07\/08<\/span><\/font><\/strong><\/strong><\/span><\/strong>&nbsp;<strong><strong><font face=\"Arial\"><span style=\"font-family: Arial\">to the<\/span><\/font><\/strong><\/strong>&nbsp;<strong><span style=\"font-weight: bold\">07<strong><strong><font face=\"Arial\"><span style=\"font-family: Arial\">\/07\/08<\/span><\/font><\/strong><\/strong><\/span><\/strong>&nbsp;<\/p>\n<p><\/span><\/font><\/p>\n<p class=\"MsoNormal\"><strong><font face=\"Arial\" color=\"#0000ff\" size=\"2\"><span style=\"font-weight: bold; font-size: 10pt; color: blue; font-family: Arial\"><\/p>\n<p><\/span><\/font><\/strong><\/p>\n<p class=\"MsoNormal\"><strong><font face=\"Arial\" color=\"#0000ff\" size=\"2\"><span style=\"font-weight: bold; font-size: 10pt; color: blue; font-family: Arial\">Fresenius acquires APP<\/p>\n<p><\/span><\/font><\/strong><\/p>\n<p class=\"MsoNormal\"><font face=\"Arial\" size=\"2\"><span lang=\"EN-GB\" style=\"font-size: 10pt; font-family: Arial\">(Les Echos online, The Financial Times online, The Wall Street Journal online \u2013 July 7, 2008)<\/p>\n<p><\/span><\/font><\/p>\n<p class=\"MsoNormal\"><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\">Fresenius has acquired APP, a US company specializing in the production of intravenous generics, for $3.7 billion. The German company will pay $23 per share of APP.<\/p>\n<p><\/span><\/font><\/p>\n<p class=\"MsoNormal\"><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\"><a href=\"http:\/\/www.aboutpharma.it\/notizia.asp?id=17194\" target=\"_blank\" rel=\"noopener\">http:\/\/www.aboutpharma.it\/notizia.asp?id=17194<\/a><\/p>\n<p><\/span><\/font><\/p>\n<p class=\"MsoNormal\"><strong><font face=\"Arial\" color=\"#0000ff\" size=\"2\"><span style=\"font-weight: bold; font-size: 10pt; color: blue; font-family: Arial\"><\/p>\n<p>&nbsp;<\/p>\n<p><\/span><\/font><\/strong><\/p>\n<p class=\"MsoNormal\"><strong><font face=\"Arial\" color=\"#0000ff\" size=\"2\"><span style=\"font-weight: bold; font-size: 10pt; color: blue; font-family: Arial\">Elected the Chairman of the Supervisory Board of Genfit<\/p>\n<p><\/span><\/font><\/strong><\/p>\n<p class=\"MsoNormal\"><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\">(Les Echos online \u2013 July 7, 2008)<\/p>\n<p><\/span><\/font><\/p>\n<p class=\"MsoNormal\"><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\">The biopharmaceutical company Genfit has appointed Xavier Guille des Buttes as Chairman of the Supervisory Board. The decision comes following the retirement of Jean-Charles Fruchart.<\/p>\n<p><\/span><\/font><\/p>\n<p class=\"MsoNormal\"><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\"><a href=\"http:\/\/www.aboutpharma.it\/notizia.asp?id=17197\" target=\"_blank\" rel=\"noopener\">http:\/\/www.aboutpharma.it\/notizia.asp?id=17197<\/a><\/p>\n<p><\/span><\/font><\/p>\n<p class=\"MsoNormal\"><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\"><\/p>\n<p>&nbsp;<\/p>\n<p><\/span><\/font><\/p>\n<p class=\"MsoNormal\"><strong><font face=\"Arial\" color=\"#0000ff\" size=\"2\"><span style=\"font-weight: bold; font-size: 10pt; color: blue; font-family: Arial\">Pierrel&#039;s projects <\/p>\n<p><\/span><\/font><\/strong><\/p>\n<p class=\"MsoNormal\"><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\">(Stock Exchange &amp; Finance: page 16 \u2013 5 July 2008)<\/p>\n<p><\/span><\/font><\/p>\n<p class=\"MsoNormal\"><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\">Pierrel&#039;s possible targets are small niche Italian companies, but also Indian companies. The resources raised with the capital increase, approximately 17.1 million euros, ve<\/p>","protected":false},"excerpt":{"rendered":"<p>Rassegna Stampa dal 04\/07\/08&nbsp;al&nbsp;07\/07\/08&nbsp; Fresenius acquisisce APP (Les Echos online, The Financial Times online, The Wall Street Journal online &#8211; 7 luglio 2008) Fresenius ha acquisito per 3,7 mld di dollari APP, societ&agrave; statunitense specializzata nella produzione di generici somministrati per via endovenosa. L&#8217;azienda tedesca pagher&agrave; 23 dollari per azione di APP. http:\/\/www.aboutpharma.it\/notizia.asp?id=17194 &nbsp; Eletto &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-12404","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/12404","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=12404"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/12404\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=12404"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=12404"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=12404"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}